Global Age-Related Macular Degeneration (AMD) Market: Trends and Opportunities (2013-2018)
Scope of the Report
The report titled “Global Age-Related Macular Degeneration (AMD) Market: Trends & Opportunities (2013-2018)” provides an in-depth analysis of the global age-related macular degeneration market with detailed analysis of various countries like the United States, U.K, Australia. It also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall AMD market has also been forecasted for the period 2013-2018, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Further, key players of the industry like Norvatis, Regeneron, Roche and Bayer are profiled.
Regional Coverage
Age-related macular degeneration (AMD) is a condition affecting older people, and involves the loss of the person's central field of vision. Several forms of AMD exist such as early AMD, late AMD, dry AMD, Wet AMD etc. Globally, the disease ranks third as a cause of blindness after cataract and glaucoma. The main factor is ageing and other risk factors may include the use of tobacco, genetic tendencies, the degree of pigmentation (with light colored eyes being at higher risk), arterial hypertension, the ultraviolet rays, and consumption of a non-balanced diet. As for the cure of the disease, there is at present no definitive treatment. Palliative treatments which are able to retard the progress of the disease include the use of intravitreous drugs or injections, lasers, dynamic phototherapy and sometimes surgery.
Globally the prevalence of AMD disease is highest in the U.S followed by the U.K and Australia. The world’s elderly population is the fastest growing age group; this is the main reason for the rising prevalence of AMD. Rising smoking habit, and unhealthy diet are the other reasons which will increase the count of AMD affected people in the near future. New types of drugs such as Eylea have come up which is indicated for the treatment of patients with neovascular (wet) age related macular degeneration and expected to substitute Lucentis and Avastin drugs in the coming years.
The report titled “Global Age-Related Macular Degeneration (AMD) Market: Trends & Opportunities (2013-2018)” provides an in-depth analysis of the global age-related macular degeneration market with detailed analysis of various countries like the United States, U.K, Australia. It also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall AMD market has also been forecasted for the period 2013-2018, taking into consideration the previous growth patterns, the growth drivers and the current and future trends. Further, key players of the industry like Norvatis, Regeneron, Roche and Bayer are profiled.
Regional Coverage
- U.S
- U.K
- Australia
- Norvatis
- Regeneron
- Roche
- Bayer
Age-related macular degeneration (AMD) is a condition affecting older people, and involves the loss of the person's central field of vision. Several forms of AMD exist such as early AMD, late AMD, dry AMD, Wet AMD etc. Globally, the disease ranks third as a cause of blindness after cataract and glaucoma. The main factor is ageing and other risk factors may include the use of tobacco, genetic tendencies, the degree of pigmentation (with light colored eyes being at higher risk), arterial hypertension, the ultraviolet rays, and consumption of a non-balanced diet. As for the cure of the disease, there is at present no definitive treatment. Palliative treatments which are able to retard the progress of the disease include the use of intravitreous drugs or injections, lasers, dynamic phototherapy and sometimes surgery.
Globally the prevalence of AMD disease is highest in the U.S followed by the U.K and Australia. The world’s elderly population is the fastest growing age group; this is the main reason for the rising prevalence of AMD. Rising smoking habit, and unhealthy diet are the other reasons which will increase the count of AMD affected people in the near future. New types of drugs such as Eylea have come up which is indicated for the treatment of patients with neovascular (wet) age related macular degeneration and expected to substitute Lucentis and Avastin drugs in the coming years.
1. EXECUTIVE SUMMARY
2. AGE-RELATED MACULAR DEGENERATION (AMD): AN INTRODUCTION
2.1 Sign and Symptoms of AMD
2.2 Causes and Risk Factors of AMD
2.3 Diagnosis of AMD
2.4 Treatment of AMD
2.4.1 Treatment of Wet AMD
2.4.2 Treatment of Dry AMD
3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET: ANALYSIS AND FORECAST
3.1 Global AMD Market: Sizing and Growth
3.1.1 Global AMD Market Size by Value: Actual and Forecast
3.1.2 Global AMD Market Size by Volume: Actual and Forecast
3.2 Global Market Share of AMD
3.2.1 AMD Market Share by Type
3.2.2 AMD Market Share by Country
3.2.3 Common Causes of Blindness- Percentage Share
3.2.4 Common Causes of Visual Impairment- Percentage Share
3.3 Worldwide Prevalence of AMD
3.3.1Prevalence of AMD by Stages
3.3.2 Prevalence of AMD by Type
3.3.3 Prevalence of AMD by Visual Impairment
4. AUSTRALIA - AGE RELATED MACULAR DEGENERATION MARKET: ANALYSIS AND FORECAST
4.1 Australian AMD Market: Sizing and Growth
4.2 Prevalence of AMD in Australia
4.2.1 Prevalence of AMD Compared to Other Diseases
4.2.2 Prevalence of AMD by Age
4.3 Causes of Blindness in Australia
5. THE U.S - AGE RELATED MACULAR DEGENERATION MARKET: ANALYSIS AND FORECAST
5.1 The US AMD Market: Sizing and Growth
5.2 Prevalence of AMD in the US
5.1.1 Prevalence of AMD by Race
5.1.2 Prevalence of AMD by Gender
6. THE U.K - AGE RELATED MACULAR DEGENERATION MARKET: ANALYSIS AND FORECAST
6.1 The UK AMD Market: Sizing and Growth
6.2 Market Sizing and Forecast by Gender
6.3 Prevalence of AMD in the UK
6.3.1 Late AMD
6.3.2 Dry AMD
6.3.3 Wet AMD
7. GLOBAL AMD MARKET: COMPETITIVE LANDSCAPE
8. MARKET DYNAMICS: GLOBAL AMD MARKET
8.1 Growth Drivers
8.2 Challenges
8.3 Market Trends
8.3.1 Radiation Therapy Treatment for AMD
8.3.2 New Drugs Eylea for the Treatment of AMD
9. COMPANY PROFILES: GLOBAL AMD MARKET
9.1 Norvatis
9.1.1 Business Overview
9.1.2 Financial Overview
9.1.3 Business Strategy
9.2 Regeneron
9.2.1 Business Overview
9.2.2 Financial Overview
9.2.3 Business Strategy
9.3 Roche
9.3.1 Business Overview
9.3.2 Financial Overview
9.3.3 Business Strategy
9.4 Bayer
9.4.1 Business overview
9.4.2 Financial Overview
9.4.3 Business Strategy
2. AGE-RELATED MACULAR DEGENERATION (AMD): AN INTRODUCTION
2.1 Sign and Symptoms of AMD
2.2 Causes and Risk Factors of AMD
2.3 Diagnosis of AMD
2.4 Treatment of AMD
2.4.1 Treatment of Wet AMD
2.4.2 Treatment of Dry AMD
3. GLOBAL AGE-RELATED MACULAR DEGENERATION MARKET: ANALYSIS AND FORECAST
3.1 Global AMD Market: Sizing and Growth
3.1.1 Global AMD Market Size by Value: Actual and Forecast
3.1.2 Global AMD Market Size by Volume: Actual and Forecast
3.2 Global Market Share of AMD
3.2.1 AMD Market Share by Type
3.2.2 AMD Market Share by Country
3.2.3 Common Causes of Blindness- Percentage Share
3.2.4 Common Causes of Visual Impairment- Percentage Share
3.3 Worldwide Prevalence of AMD
3.3.1Prevalence of AMD by Stages
3.3.2 Prevalence of AMD by Type
3.3.3 Prevalence of AMD by Visual Impairment
4. AUSTRALIA - AGE RELATED MACULAR DEGENERATION MARKET: ANALYSIS AND FORECAST
4.1 Australian AMD Market: Sizing and Growth
4.2 Prevalence of AMD in Australia
4.2.1 Prevalence of AMD Compared to Other Diseases
4.2.2 Prevalence of AMD by Age
4.3 Causes of Blindness in Australia
5. THE U.S - AGE RELATED MACULAR DEGENERATION MARKET: ANALYSIS AND FORECAST
5.1 The US AMD Market: Sizing and Growth
5.2 Prevalence of AMD in the US
5.1.1 Prevalence of AMD by Race
5.1.2 Prevalence of AMD by Gender
6. THE U.K - AGE RELATED MACULAR DEGENERATION MARKET: ANALYSIS AND FORECAST
6.1 The UK AMD Market: Sizing and Growth
6.2 Market Sizing and Forecast by Gender
6.3 Prevalence of AMD in the UK
6.3.1 Late AMD
6.3.2 Dry AMD
6.3.3 Wet AMD
7. GLOBAL AMD MARKET: COMPETITIVE LANDSCAPE
8. MARKET DYNAMICS: GLOBAL AMD MARKET
8.1 Growth Drivers
8.2 Challenges
8.3 Market Trends
8.3.1 Radiation Therapy Treatment for AMD
8.3.2 New Drugs Eylea for the Treatment of AMD
9. COMPANY PROFILES: GLOBAL AMD MARKET
9.1 Norvatis
9.1.1 Business Overview
9.1.2 Financial Overview
9.1.3 Business Strategy
9.2 Regeneron
9.2.1 Business Overview
9.2.2 Financial Overview
9.2.3 Business Strategy
9.3 Roche
9.3.1 Business Overview
9.3.2 Financial Overview
9.3.3 Business Strategy
9.4 Bayer
9.4.1 Business overview
9.4.2 Financial Overview
9.4.3 Business Strategy
LIST OF FIGURES
Figure 1: Causes of AMD Disease
Figure 2: Global AMD Market Size by Value: 2008 to 2012 (US$ Million)
Figure 3: Global AMD Market Size by Value Forecast: 2013 to 2018 (US$ Million)
Figure 4: Global AMD Market Size by Volume: 2010 to 2012 (Million)
Figure 5: Global AMD Market Size Forecast by Volume: 2013 to 2018 (Million)
Figure 6: Global Market Share of AMD by Type (2012)
Figure 7: Global Market Share of AMD Market by Country (2011)
Figure 8: Common Causes of Blindness – Percentage Share (2012)
Figure 9: Common of Causes of Visual Impairment – Percentage Share (2012)
Figure 10: Prevalence of Visual Impairment due to AMD by Stages: 2008 to 2012
Figure 11: Prevalence of Visual Impairment due to AMD by Stages Forecast: 2013 to 2018
Figure 12: Size of Australian AMD Market: 2010 to 2012
Figure 13: Size of Australian AMD Market Forecast: 2013 to 2018
Figure 14: AMD Vis-à-vis Other Diseases - Prevalence in Australia: 2012
Figure 15: Causes of Blindness in Australia (2012)
Figure 16: The U.S AMD Market Size: 2009 to 2012
Figure 17: The U.S AMD Market Size Forecast: 2013 to 2018
Figure 18: Prevalence of AMD in the U.S by Race 2011 in Percentage
Figure 19: Prevalence share of AMD by Race in the U.S (2011)
Figure 20: Prevalence Share of AMD by Gender in the U.S (2011)
Figure 21: Prevalence Count of AMD by Gender in the U.S (2012)
Figure 22: U.K AMD Market Size: 2010 to 2012
Figure 23: U.K AMD Market Size Forecast: 2013 to 2018
Figure 24: U.K AMD Market Size by Gender: 2010 to 2012
Figure 25: U.K AMD Market Size by Gender Forecast: 2013 to 2018
Figure 26: Prevalence of Late AMD by Age in 2011 (Thousand Cases)
Figure 27: Prevalence of Dry AMD in 2011 by Age (thousand Cases)
Figure 28: Prevalence of Wet AMD by Age in 2011 (Thousand Cases)
Figure 29: Revenue of Companies according to Product: 2012 (US$ Million)
Figure 30: Market Share of AMD Products (2011)
Figure 31: Market Share of Different Companies: 2010 to 2012
Figure 32: Population of 60 and Above Age: 2007 to 2012 (Million)
Figure 33: Female Population: 2007 to 2012 (Million)
Figure 34: Smoking Population Percentage According to Age Group (2011)
Figure 35: Awareness Level of AMD by Country (2011)
Figure 36: Eylea Drug Used for the Treatment of AMD
Figure 37: Sales Forecast of Eylea Drug: 2012 to 2016 (US$ Million)
Figure 38: Norvatis Revenue: 2008 to 2012 (US$ Million)
Figure 39: Norvatis Revenue Share by Region (2012)
Figure 40: Regeneron Revenue: 2008 to 2012 (US$ Million)
Figure 41: Roche Revenue: 2008 to 2012 (US$ Million)
Figure 42: Bayer Revenue: 2008 to 2012 (US$ Million)
Figure 1: Causes of AMD Disease
Figure 2: Global AMD Market Size by Value: 2008 to 2012 (US$ Million)
Figure 3: Global AMD Market Size by Value Forecast: 2013 to 2018 (US$ Million)
Figure 4: Global AMD Market Size by Volume: 2010 to 2012 (Million)
Figure 5: Global AMD Market Size Forecast by Volume: 2013 to 2018 (Million)
Figure 6: Global Market Share of AMD by Type (2012)
Figure 7: Global Market Share of AMD Market by Country (2011)
Figure 8: Common Causes of Blindness – Percentage Share (2012)
Figure 9: Common of Causes of Visual Impairment – Percentage Share (2012)
Figure 10: Prevalence of Visual Impairment due to AMD by Stages: 2008 to 2012
Figure 11: Prevalence of Visual Impairment due to AMD by Stages Forecast: 2013 to 2018
Figure 12: Size of Australian AMD Market: 2010 to 2012
Figure 13: Size of Australian AMD Market Forecast: 2013 to 2018
Figure 14: AMD Vis-à-vis Other Diseases - Prevalence in Australia: 2012
Figure 15: Causes of Blindness in Australia (2012)
Figure 16: The U.S AMD Market Size: 2009 to 2012
Figure 17: The U.S AMD Market Size Forecast: 2013 to 2018
Figure 18: Prevalence of AMD in the U.S by Race 2011 in Percentage
Figure 19: Prevalence share of AMD by Race in the U.S (2011)
Figure 20: Prevalence Share of AMD by Gender in the U.S (2011)
Figure 21: Prevalence Count of AMD by Gender in the U.S (2012)
Figure 22: U.K AMD Market Size: 2010 to 2012
Figure 23: U.K AMD Market Size Forecast: 2013 to 2018
Figure 24: U.K AMD Market Size by Gender: 2010 to 2012
Figure 25: U.K AMD Market Size by Gender Forecast: 2013 to 2018
Figure 26: Prevalence of Late AMD by Age in 2011 (Thousand Cases)
Figure 27: Prevalence of Dry AMD in 2011 by Age (thousand Cases)
Figure 28: Prevalence of Wet AMD by Age in 2011 (Thousand Cases)
Figure 29: Revenue of Companies according to Product: 2012 (US$ Million)
Figure 30: Market Share of AMD Products (2011)
Figure 31: Market Share of Different Companies: 2010 to 2012
Figure 32: Population of 60 and Above Age: 2007 to 2012 (Million)
Figure 33: Female Population: 2007 to 2012 (Million)
Figure 34: Smoking Population Percentage According to Age Group (2011)
Figure 35: Awareness Level of AMD by Country (2011)
Figure 36: Eylea Drug Used for the Treatment of AMD
Figure 37: Sales Forecast of Eylea Drug: 2012 to 2016 (US$ Million)
Figure 38: Norvatis Revenue: 2008 to 2012 (US$ Million)
Figure 39: Norvatis Revenue Share by Region (2012)
Figure 40: Regeneron Revenue: 2008 to 2012 (US$ Million)
Figure 41: Roche Revenue: 2008 to 2012 (US$ Million)
Figure 42: Bayer Revenue: 2008 to 2012 (US$ Million)
LIST OF TABLES
Table 1: Classification Scale Used to Define Four Stages of AMD
Table 2: Signs and Symptoms of AMD
Table 3: Most common Causes and Risk Factors of AMD
Table 4: Prevalence of AMD by Stage (% of Age Group)
Table 5: Prevalence of Late AMD by Type (2011)
Table 6: Estimated Cumulative 10 year Incidence Rate of AMD by Age
Table 7: Prevalence of AMD in the U.S by Race 2011 in Percentage
Table 8: Prevalence Count of AMD by Race in the U.S (2012)
Table 9: Name of Companies and their Products
Table 1: Classification Scale Used to Define Four Stages of AMD
Table 2: Signs and Symptoms of AMD
Table 3: Most common Causes and Risk Factors of AMD
Table 4: Prevalence of AMD by Stage (% of Age Group)
Table 5: Prevalence of Late AMD by Type (2011)
Table 6: Estimated Cumulative 10 year Incidence Rate of AMD by Age
Table 7: Prevalence of AMD in the U.S by Race 2011 in Percentage
Table 8: Prevalence Count of AMD by Race in the U.S (2012)
Table 9: Name of Companies and their Products
